Medicus Pharma (MDCX) Non-Current Debt (2025 - 2026)

Medicus Pharma's (MDCX) quarterly Non-Current Debt came in at $25865.0 in Q4 2025, down 12.21% on a QoQ basis from $29462.0 in Q3 2025.

Medicus Pharma (MDCX) Non-Current Debt (2025 - 2026) Analysis & Trends

Medicus Pharma (MDCX) has 1 years of Non-Current Debt data on file, last reported at $25865.0 in Q4 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $25865.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25865.0 (changed N/A YoY) and the FY2025 annual result came in at $25865.0, changed N/A from the prior year.
Non-Current Debt fell to $25865.0 in Q4 2025, from $29462.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $29462.0 in Q3 2025 to a low of $25865.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn	37.34 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn	62.48 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn	51.08 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn	-
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn	23.68 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn	57.30 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn	26.25 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn	60.50 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn	-18.71 Bn
10	Medicus Pharma	14.88 Mn	-298,205.43	-	17.98 Mn

Download Data